A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Trial details
- Registry ID
- NCT02604199
- Phase
- Phase 2
The FDA approved entecavir (Baraclude) on 29 Mar 2005.
Drug identity checked against registry records
Also recorded as Baraclude
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2005-03-29Day | entecavir | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021797", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["BARACLUDE"], "active_ingredients": ["ENTECAVIR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20050329", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |